Astrazeneca Share Discussion Threads

[onehanded] 21/4/2021 10:47

tablet form to help recover if test positive, as per PM speak yesterday in trail from AZN.

[smcni1968] 21/4/2021 10:43

Has anything been said recently about AZN's other experimental COVID drug?

[nicd] 21/4/2021 09:12

More fool them (the French)So long as the shipments are paid for

[montyhedge] 20/4/2021 12:50

Show where I said that 6800p yes.

[john nada] 20/4/2021 10:17

The only vaccine surrender monkeys around the world appear to be the British. What an embarassment. Too much goggle box for the proles.

Vive La France

[smcni1968] 20/4/2021 10:12

Most large Alexion shareholders that don't want to or can't own Astra will have sold already to a hedge fund or bank that in turn will have shorted Astra to lock in the spread

[montyhedge] 20/4/2021 10:01

Pound strong 1.40, hits profits and dividends of overseas dollar earners.

[imastu pidgitaswell] 20/4/2021 08:45

Well you keep wondering monty - we're still waiting for the £62 you promised...🙄

[montyhedge] 19/4/2021 21:21

So Alexion merger should close September, I think they end up with 15% of Astra, wonder what Alexion shareholders will do, sell or hold.

[onehanded] 19/4/2021 08:24

they are except from direct law suit as signed emergency product agreement, which any major side effects are directly related to the country agreeing the use of their vaccine for it's own population. So, no lawsuit can be taken against them but could be governments.

[montyhedge] 19/4/2021 08:19

Only no profit on vaccine, but lawsuits, unbelievable.

[montyhedge] 19/4/2021 08:18

Yes lawsuits will start coming in I would imagine.

[philanderer] 19/4/2021 00:13

COVID-19: Family of Italian woman who died after Oxford-AstraZeneca vaccine launch legal action

[beckers2008] 18/4/2021 00:44

From Fierce Pharma.

Surprise: AstraZeneca's $39B Alexion buy clears a newly vigilant FTC without a hitch.

Just as pharma watchers were bracing themselves for the brunt of renewed antitrust scrutiny around large biopharma transactions, AstraZeneca’s mega-acquisition of Alexion Pharma sailed through the much-dreaded review unscathed.

In an anticlimactic announcement Friday, AZ said the U.S. Federal Trade Commission has cleared the $39 billion deal first unveiled in December.

None of the extra antitrust hurdles that analysts had feared for the marriage actually happened. The FTC didn’t attach any extra conditions to the deal. In fact, the go-ahead simply followed the 30-day waiting period triggered when the companies refiled their transaction for review on March 16.

Analysts had expected the deal to face tough resistance from the new Democrat-controlled FTC after the agency threatened more aggressive oversight in mid-March, revamping its approach to examining biopharma deals in particular.

As the largest biopharma M&A deal in 2020, the Alexion purchase was one obvious target the new agency could have used to sharpen its regulatory knife. AZ’s almost concurrent announcement in March—that it had chosen to withdraw and refile the M&A notification form after “informal discussions” with the FTC—only added further uncertainty to the deal.

In a recent note that reflected the general view among pharma watchers, SVB Leerink analyst Geoffrey Porges predicted a high likelihood that FTC would either block the transaction or saddle it with “onerous conditions.”

As the new FTC works with foreign counterparts and other U.S. agencies to iron out its newly vigilant approach, one likely scenario was that the AZ-Alexion review period would be extended with the notorious “second request,” in which the agency asks for additional documents related to a transaction. That apparently didn’t happen.

The Biden FTC is now pursuing a view that investigation of biopharma deals shouldn’t focus solely on specific product overlap but more broadly on whether the involved companies’ practices harm innovation. Previous anticompetitive conduct, such as pay-for-delay settlements, as well as drug-price hikes, could all come into consideration.

From a portfolio perspective, AstraZeneca and Alexion have no obvious overlap. Alexion is viewed as a rare disease expert, whereas AZ isn’t involved in that arena. In fact, AZ ranked very low on analysts’ lists of possible Alexion buyers before the deal was announced.

AZ is also buying Alexion for the latter’s expertise in immunology. There, the two companies don’t have products that compete against each other.

During the Trump administration, the FTC forced product selloffs in Mylan’s merger with Pfizer’s generic unit Upjohn, AbbVie’s purchase of Allergan and Bristol Myers Squibb’s acquisition of Celgene.

It also delayed Roche’s takeover of Spark Therapeutics as regulators tried to determine whether Roche would sabotage development of a Spark hemophilia gene therapy to prevent competition with its own antibody drug Hemlibra.

Now, AZ and Alexion don’t have to worry about any of that. The FTC’s go-ahead follows clearances from other anticompetition regulators in Canada, Brazil, Russia and others, with the U.K., EU and Japan still pending, AZ said. The company still expects the deal to close in the third quarter.

[bluemango] 17/4/2021 10:23

Trouble is, there's generally a tiny bit of truth in all these things; the problem is when they get blown up out of proportion.

E.g. it's ridiculous that someone dying in a road accident gets recorded as dying from Covid if it just happens to have been within 28 days of a positive test. And it's certainly debatable how effective lockdowns and masks are when you compare with countries like Sweden. When your aim is mass compliance, governments have to introduce apparent certainty into things that most thinking people regard as open to question.

But when you start to question, that then starts to feed the conspiracy theorists. It's a tricky thing for governments (and their critics) to strike the right balance.

[blusteradjuster] 17/4/2021 09:34

It’s funny isn’t it (well, not really).

The conspiracy nuts/anti-vaxxers that have spent a year telling us:

- they died with COVID not of COVID

Are the same conspiracy nuts/anti-vaxxers who now tell us:

- they died of vaccine not with vaccine


Perhaps Darwinism will thin them out a bit ... if they practice what they reach.

[alphorn] 17/4/2021 09:22

As previously posted it is Vaccitech, the start-up, that owns the IP behind the AZN vaccine, and will eventually receive royalty income.

The spinout published its prospectus for an IPO on Nasdaq last week.

The filing revealed how much the start-up stands to receive from vaccine sales. If and when AZN starts selling the shot for a profit after the pandemic — which according to their contract could be as early as July 2021.

[bluemango] 17/4/2021 08:58

Yes, but did they have either toast or porridge at breakfast? If they did, there's the correlation and clear cause and effect. Nothing to do with the vaccine.

One thing this Covid thing has done is give free rein to all the nutty conspiracy theorists. Extraordinary.

[insideryou] 17/4/2021 07:57

F.O.I Request shows 2,207 died within 28 days of having the Covid Vaccine in Scotland during February



A freedom of information request made to Public Health Scotland has revealed that 2,207 people died within twenty-eight days of having either the Pfizer / BioNTech mRNA vaccine or the Oxford / AstraZeneca viral vector vaccine during the month of February.




The request for the information was made on the 20th February 2021 and asked –

“Could you please provide the total number of deaths for any reason within 28 days of having a Covid vaccine from the start of the vaccination roll-out date?”

To which Public Health Scotland responded with this–

“Using the latest mortality data available (Up to 26th February), 2,207 people have died within 28 days of vaccination (number of days between vaccine and death is 0-27 where 0 is the day of vaccination).”

But Public Health Scotland then added a caveat to this data by stating –

“Please note that these deaths are due to any cause; PHS is not currently aware of any deaths in Scotland that are considered conclusively linked to vaccination.”


That’s great, but isn’t it slightly hypocritical to apply this logic to vaccination deaths? When this logic has been absent for the past 12 months concerning Covid deaths.

The daily death figures of Covid-19 deaths plastered on every news channel and newspaper daily are totalled via counting any deaths that occur within 28 days of a positive test for SARS-CoV-2, the virus allegedly caused Covid-19. This means that if somebody is to die crossing the road, but they had received a positive test for SARS-CoV-2 in the 28 days prior, they are added to the daily Covid death statistics.

Daily Covid death statistics have been used to justify 12 months of dictatorial tyranny. Death statistics have been used to scare a naive majority into compliance. Death statistics which have been used to decimate the economy, destroy small business, ruin livelihoods, and damage mental health.

So are the authorities telling us it’s okay to use this logic to count deaths when it comes to something as serious as essentially destroying millions of lives? But it’s not okay to use this logic to count deaths when it comes to taking an experimental vaccine in stage three trials until 2023 and is only authorised for emergency use meaning the manufacturer is not liable for any adverse reaction resulting in injury.

Please wake up and smell the roses people, it’s now or never.

[philanderer] 17/4/2021 00:35

"EU Likely to Drop AstraZeneca, J&J as Future Vaccine Options"

[philanderer] 17/4/2021 00:34

"Astrazeneca boss Pascal Soriot will fly back from Australia before the end of the month as he prepares to face disgruntled shareholders"

[philanderer] 16/4/2021 00:24

Brain clots 'more likely' with Covid infection than vaccine

[freddie ferret] 15/4/2021 23:00

Huncher.

In 12 months none of the vaccines currently in use will be able to contol the variants that will evolve over the next twelve months imho.

[poikka] 15/4/2021 22:29

"AstraZeneca won’t make a profit off the 3.3 billion doses it intends to deliver this year. In contrast, Moderna expects to make $18bn (£13bn) in revenue from its vaccine and Pfizer/BioNTech $15bn (£11bn). Both manufacturers are almost exclusively accommodating western populations, and stand to make billions from doing so."

The potential is there, though.